deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03100032

Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis (Spine1)

A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)

Sponsor: Novadip Biosciences

Conditions Spondylolisthesis
Interventions NVD-001 Standard of Care
Updated 13 times since 2017 Last updated: Aug 11, 2021 Started: Jan 31, 2017 Primary completion: Jan 31, 2021 Completion: Jun 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Spondylolisthesis and is currently completed. Novadip Biosciences leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Apr 2019 · 9 months · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Apr 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jul 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2017 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novadip Biosciences
Data source: Novadip Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations